Market: NASD |
Currency: USD
Address: 18 Hasivim Street
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
📈 PolyPid Ltd. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$12.50
-
Upside/Downside from Analyst Target:
273.13%
-
Broker Call:
8
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
50-100%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
2025-11-12
-
EPS Estimate:
-0.52
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2023 |
- |
$0.033333 |
- |
2023-09-21 |
- |
Stock split |
|
Total Amount for 2023: $0.033333 |
📅 Earnings & EPS History for PolyPid Ltd.
| Date | Reported EPS |
|---|
| 2025-11-12 (estimated upcoming) | - |
| 2025-08-13 | -0.78 |
| 2025-05-14 | -0.7 |
| 2025-02-12 | -1.07 |
| 2024-11-13 | -1.22 |
| 2024-08-14 | -1.25 |
| 2024-05-08 | -1.37 |
| 2024-02-14 | -3.84 |
| 2023-11-08 | -3.4 |
| 2023-08-09 | -10.8 |
| 2023-05-10 | -8.4 |
| 2023-02-08 | -9.6 |
| 2022-11-09 | -14.4 |
| 2022-08-10 | -18.3 |
| 2022-05-11 | -18.9 |
| 2022-02-09 | -21.3 |
| 2021-11-10 | -15.9 |
| 2021-08-11 | -16.8 |
| 2021-05-12 | -14.1 |
| 2021-02-10 | -12.3 |
| 2020-11-11 | -10.5 |
| 2020-08-19 | -191.1 |
📰 Related News & Research
No related articles found for "polypid ltd".
